Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a commercial-stage biopharmaceutical company dedicated to redefining the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities, collaborating to develop and deliver innovative medicines with the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve.
In the company’s own words · 10-K filed Feb 12, 2026 · SEC EDGAR
Agios Pharmaceuticals, Inc. (AGIO) reported revenue of $21M in Q1 2026 (quarter ended March 31, 2026), up 138% from the same quarter a year earlier. That came with a gross margin of 94% and net loss of $99M. For the full year FY2025, revenue was $54M (+48% year on year) and net income −$413M.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.